SCIENTIFIC JOURNAL of the Hungarian Society of Cardiology

Akut koronáriaszindróma miatt intervención átesett betegeink lipidcsökkentő kezelése és ajánlás a beavatkozás utáni ellenőrzésekre

█ Original article

Authors:
Márk László1, Dani Győző2, Ozsváth Lídia1, Szabó-Györke István3, Katona András1, Jambrik Zoltán1
1Békés Megyei Központi Kórház, Pándy Kálmán Tagkórház, Gyula
2Városi Kórház, Orosháza
3Békés Megyei Központi Kórház, Réthy Pál Tagkórház, Békéscsaba

The lipid lowering therapy of patients after intervention due to acute coronary syndrome and a recommendation for the further controls
Introduction: The lipid lowering therapy has become one of the basic elements of the cardiovascular prevention and also the attainment of the target levels recommended by the guidelines has an intensified importance in case of patients after acute coronary syndrome (ACS), but it is well known that all over the world this doesn’t reach an acceptable level.
The relevance of this treatment is underlined by the fact that in the recommendations published in 2019 the LDL-cholesterol (LDL-C) goal level in case of very high risk patients has been lowered from 1.8 to 1.4 mmol/l.
Aim: The evaluation of the lipid lowering therapy at the time of hospital discharge and the attainment of lipid levels in the first year after the intervention in a county hospital possessing hemodynamic possibilities.
Method: A retrospective data collection was performed in the database of the three hospitals of the county, regarding to therapy at discharge and the lipid levels followed over one year in case of patients undergone by coronary intervention due to ACS in 2017.
Results: We treated 513 patients with ACS in 2017, 38.6% of them suffered from ST segment elevation-, 56.5% with non-ST segment elevation myocardial infarction and 4.9% from unstable angina. The mean age was 67.9 years. At the time of hospital discharge 98.5% of patients got recommendation for statin treatment (1.5% for 20 mg rosuvastatin, 94% for 40 mg rosuvastatin and 3% for combination of 40 mg rosuvastatin + 10 mg ezetimibe). In the database of these hospitals, after 6 month of the discharge only 277 (54%), after one year 269 (52%) patients had lipid measurement results. The LDL-C average value (mmol/l, [IQ-range] was 1.97 (1.26–2.77) after half of a year, and 2.04 (1.29–2.36) after one year, the attainment rate of 1.8 mmol/l was 52.7% after 6 months of intervention, 48.0% after one year, the new target value –1.4 mmol/l was reached in 18.9% and after one year in 18.7% of patients.
Conclusions: The lipid lowering therapy suggested at discharge to patients suffering from ACS correlates with recommendations of the guidelines, but the goal attainment at half- and at one year is below of expectations. It would be advisable to give exact dates for the forthcoming control exams in the final report of patients treated with ACS and to give them a referral for the first lipid profile lab analysis at 4-6 weeks.

ISSUE: CARDIOLOGIA HUNGARICA | 2020 | VOLUME 50, ISSUE 1

click here to read the full article

click here to read the pdf